IP Library Granted Patent US 9,072,728
Granted Patent B2
US 9,072,728 · App. 10/572,667 · Granted Jul 7, 2015

Treatment of severe distal colitis

Inventors: Paul Rufo (West Roxbury, MA); Wayne I. Lencer (Jamaica Plain, MA)
Assignee: Children's Medical Center Corporation
A61K31/4174
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,072,728
App. No.
10/572,667
Granted
Jul 7, 2015
Kind
B2
Abstract

This invention relates to methods and materials involved in the treatment of diseases with severe distal colitis component, and more specifically non-fungal and/or non-microbial induced mucositis of the distal intestinal tract. Kits and pharmaceutical compositions for medical treatments also are provided.

Claims (9)

1. A method for treating a subject having non-fungal induced mucositis of the distal intestinal tract, comprising administering locally to the distal intestinal tract of the subject clotrimazole in an amount effective to reduce or eliminate the non-fungal induced mucositis of the distal intestinal tract, wherein the effective amount is administered in a single dosage in the range of 2,000 mg to 10,000 mg.

2. The method of claim 1 , wherein the effective amount is administered at a frequency of administration from four times a day to once a month.

3. The method of claim 1 , wherein the non-fungal induced mucositis of the distal intestinal tract is selected from the group consisting of pouchitis, ulcerative colitis, Crohn's disease, allergic colitis, autoimmune colitis, autoimmune enteropathy, bacterial colitis, diversion colitis and lymphocytic colitis.

4. The method of claim 1 , wherein the non-fungal induced mucositis of the distal intestinal tract is pouchitis.

5. The method of claim 1 , wherein the mucositis of the distal intestinal tract is non-microbial induced.

6. The method of claim 1 , wherein the effective amount is from 2,500 mg to 10,000 mg at a frequency of from twice a day to once every two weeks.

7. The method of claim 1 , wherein the subject is a human.

8. The method of claim 1 , further comprising administering to the subject an amount of one or more non-azole compounds effective to treat the non-fungal induced mucositis of the distal intestinal tract.

9. The method of claim 8 , wherein the non-azole compounds are selected from a list consisting of anti-inflammatory or anti-bacterial compounds.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 18, 2010
From: CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024562/0638 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2010
From: RUFO, PAUL; LENCER, WAYNE I.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 024123/0104 →
Continuity (2)
Provisional Application 60504516 · Sep 18, 2003
Related Publication 20090118343A1 · May 7, 2009